Alnylam Pharmaceuticals pricerALNY

Alnylam Pharmaceuticals Key Takeaways

According to real-time chart analysis, the current technical structure of Alnylam Pharmaceuticals (rALNY) indicates that the key market support level is at $197.81 (52-week low), while the primary resistance level is at $225.00. If the price moves out of this range, it may trigger a new trend. Overall, the market is currently in a Correction and Consolidation phase following a significant sell-off, with price fluctuations primarily concentrated within these technical boundaries.

Technical Indicators

RSI: Currently at 36.76, indicating that market momentum is Neutral to Oversold.
MACD: The signal is currently Bullish Crossover (at -7.34), suggesting a potential short-term recovery despite the recent downtrend.
MA: The price is currently located below the 50-day and 200-day moving averages ($292.29 and $355.33 respectively), showing that the medium-to-long term trend remains Bearish.

Market Drivers

The current price and market performance of Alnylam Pharmaceuticals are primarily influenced by the following factors:
• Guidance Revision: The company recently lowered its 2026 revenue guidance for the TTR franchise (Amvuttra and Onpattro) to $4.2B–$4.5B, citing a normalization of "pent-up demand."
• Competitive Landscape: Increased competition in the ATTR-cardiomyopathy market from rivals like Pfizer and BridgeBio is weighing on investor sentiment.
• Earnings Performance: While Q2 earnings per share ($1.84) beat estimates, a miss on the total revenue forecast triggered a sharp market reaction.

Trading Signals

Based on the current technical structure and market momentum, the following trading strategies are provided for reference:

Potential Buy Zone

• If the price approaches $197.00 - $200.00 and shows signs of stabilization, it may form a short-term buying opportunity.
• If the price breaks above $225.00 with significant volume, it could confirm the start of a relief rally.

Risk Scenario

• If the price falls below $197.81, the market may enter a further stage of discovery, potentially testing the $180.00 psychological level.

Buy Strategy

Based on the current market structure, analysts offer the following strategies:

Conservative Investors

• Wait for the price to effectively stabilize above the $215.00 level before considering entry.
• Alternatively, wait for a successful retest of the $198.00 support without a breakdown.

Trend Investors

• If the price breaks the $225.00 resistance, a new upward trend toward the gap-fill area may form.
• The next target price in this scenario would be $276.00.

Long-term Investors

• As long as the price remains above the $197.00 macro support, the long-term thesis for the RNAi therapeutics leader remains intact, allowing for gradual accumulation.

Trends Summary

Market Insights

From a short-term perspective, Alnylam Pharmaceuticals has exhibited a Sharp Decline followed by Horizontal Consolidation over the past 7 days, and market sentiment is generally Fearful but Stabilizing.From a medium-term structural analysis, the price is currently trapped between the support at $197.81 and resistance at $225.00.

Market Outlook

If the price breaks above $225.00, the next target could be $276.00.
If the price falls below $197.81, the next target could be $185.00.

Market Consensus

The consensus among multiple analysts is that while Alnylam Pharmaceuticals may face continued volatility or sideways movement in the short term due to guidance concerns, the medium-term trend could shift toward Recovery if the key support at $197.81 is maintained.